Hopefully these guys don't know something we don't.
https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-Enters-Agreement-Providing-Exclusive-Right-to-Acquire-Promedior-Inc-and-its-Novel-PRM-151-in-Development-for-Fibrotic-Diseases/default.aspx
In 2015 BMS paid Premedior $150 upfront and committed a total of $1.25 billion to the deal if PRM-151 was shown to work in phase 2 trial for idiopathic pulmonary fibrosis (IPF) and myelofibrosis (MF).
PRM-151 is a recombinant form of human pentraxin-2 protein, an endogenous regulator of the inflammatory and fibrotic response to tissue injury. Hmmm anti-fibrotic protein sounds familiar.
Notably, 72 weeks was required to see improvements in hemoglobin, platelets, spleen and symptoms.
BMS walked away from the deal and but $1.4 bill was stumped by Roche.
https://www.fiercebiotech.com/biotech/after-bms-said-no-roche-puts-1-4b-table-for-promedior-boosting-fibrotic-pipeline
Although encouraging early results, no further clinical development has been made.
Add to My Watchlist
What is My Watchlist?
